Status:
UNKNOWN
Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.
Lead Sponsor:
Bnai Zion Medical Center
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
The purpose of the study is to check whether development of depression as a side effect of interferon alpha treatment in chronic carriers of hepatitis C can be prevented by omega-3 fatty acids.
Detailed Description
Omega-3 fatty acids are known as an alternative treatment for different conditions, including mental conditions, such as depression. We assume that combining omega-3 with the treatment by interferon a...
Eligibility Criteria
Inclusion
- Chronic carriers of hepatitis C who start a course of interferon alpha treatment, and are treated in the liver clinic of Bnai Zion hospital.
Exclusion
- Disagreement to participation in trial.
- Diagnosed and active mental illness.
- Encephalopathic patients.
- Patients with limited ability to understand the questionnaires or the informed consent process.
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
End Date :
December 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00408304
Start Date
December 1 2006
End Date
December 1 2007
Last Update
December 6 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bnai Zion Medical Center
Haifa, Israel